The Food and Drug Administration (FDA) has recently approved the first trifocal intraocular lens from Alcon, for use in patients undergoing cataract surgery in the United States.
The Food and Drug Administration (FDA) has recently approved the first trifocal intraocular lens from Alcon, for use in patients undergoing cataract surgery in the United States.
Clinical studies demonstrated that the lens offers patients outstanding near, intermediate and distance vision while also reducing the need for glasses post-op.
With more than 4 million cataract surgeries being performed in the United States every year, Alcon claims that its new class of intraocular lens (IOL) offers patients uninterrupted vision and outperforms other premium lenses. This PanOptix intraocular lens proved to provide high patient satisfaction in clinical studies with 99% percent of recipients saying they would choose the same lens again.
Training of U.S. ophthalmologists by Alcon will begin this year and continuing through early 2020. Alcon also plans to launch a website dedicated to the PanOptix lens as well as launching a multimedia awareness campaign to inform patients.*
Doctor-formulated AREDS 2 for Macular Degeneration
